<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diffuse Large B-Cell Lymphoma - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Diffuse Large B-Cell Lymphoma</span>
        </nav>

        <header class="page-header">
            <h1>Diffuse Large B-Cell Lymphoma</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018905" target="_blank">
                        MONDO:0018905
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">B-cell non-Hodgkin lymphoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, representing 30-40% of cases. It is characterized by diffuse proliferation of large B-lymphoid cells and is clinically aggressive but potentially curable with immunochemotherapy. Gene expression profiling identifies two major molecular subtypes: germinal center B-cell (GCB) type with better prognosis and activated B-cell (ABC) type with inferior outcomes. MYC, BCL2, and BCL6 rearrangements define high-grade &#34;double-hit&#34; or &#34;triple-hit&#34; lymphomas with aggressive behavior. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains standard frontline therapy, with novel approaches for relapsed disease.
            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2026-01-26T02:55:13Z">2026-01-26</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-01-26T04:02:22Z">2026-01-26</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#histopathology">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">hematologic malignancy</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Lymphoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Germinal Center B-cell (GCB) Type
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">DLBCL with gene expression profile resembling normal germinal center B cells. Characterized by expression of GCB markers (CD10, BCL6, GCET1). Often harbors BCL2 translocation and EZH2 mutations. Better prognosis than ABC type with R-CHOP, with approximately 60-70% cure rates.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Activated B-cell (ABC) Type
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">DLBCL with gene expression profile resembling activated peripheral B cells. Shows constitutive NF-kB activation, often through mutations in CD79A/B, CARD11, MYD88, or deletions of A20. Inferior prognosis with standard R-CHOP. May benefit from targeted agents inhibiting NF-kB pathway.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Double-hit lymphoma (DHL) with concurrent MYC and BCL2 translocations, or triple-hit with MYC, BCL2, and BCL6 rearrangements. Highly aggressive with poor outcomes to standard R-CHOP. Requires intensified therapy.</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Germinal Center B-cell Origin</div>
                
                <div class="item-desc">DLBCL arises from germinal center or post-germinal center B cells undergoing somatic hypermutation and class switch recombination. These processes introduce DNA double-strand breaks that can lead to oncogenic translocations. The cell of origin determines molecular subtype and clinical behavior.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        centrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0009111" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        centroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0009112" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        lymph node
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000029" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">BCL2 Overexpression and Apoptosis Resistance</div>
                
                <div class="item-desc">BCL2 translocation t(14;18) occurs in approximately 30% of GCB-DLBCL, placing BCL2 under immunoglobulin enhancer control. Resulting BCL2 overexpression blocks the mitochondrial apoptosis pathway, allowing survival of cells that would normally die in the germinal center.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        apoptotic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006915" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">MYC-Driven Proliferation</div>
                
                <div class="item-desc">MYC rearrangements occur in 10-15% of DLBCL, most commonly with IGH but also with non-immunoglobulin partners. MYC overexpression drives cellular proliferation and metabolism. When combined with BCL2 rearrangement (double-hit lymphoma), creates highly aggressive disease.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NF-kB Constitutive Activation</div>
                
                <div class="item-desc">ABC-DLBCL shows constitutive NF-kB activation through various mechanisms including BCR signaling mutations (CD79A/B), CARD11 mutations, MYD88 L265P mutation, or A20 deletion. NF-kB promotes survival and contributes to the aggressive behavior of ABC subtype.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        signal transduction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007165" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Lymphoma Cell Accumulation</div>
                
                <div class="item-desc">The combination of blocked apoptosis, enhanced proliferation, and constitutive survival signaling leads to aggressive expansion of large B-cell lymphoma involving lymph nodes and extranodal sites.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000236" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        lymph node
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000029" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card" id="histopathology">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Diffuse Large B-Cell Lymphoma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Diffuse large B-cell lymphoma is the most common pathologic subtype.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16613685" target="_blank">PMID:16613685</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Diffuse large B-cell lymphoma is the most common pathologic subtype."</div>
                
                
                <div class="evidence-explanation">Abstract notes DLBCL as the most common pathologic subtype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Lymphoma_Cell_Accumulation[&#34;Lymphoma Cell Accumulation&#34;]
    BCL2_Overexpression_and_Apoptosis_Resistance[&#34;BCL2 Overexpression and Apoptosis Resistance&#34;]
    MYC_Driven_Proliferation[&#34;MYC-Driven Proliferation&#34;]
    NF_kB_Constitutive_Activation[&#34;NF-kB Constitutive Activation&#34;]
    Germinal_Center_B_cell_Origin[&#34;Germinal Center B-cell Origin&#34;]

    Germinal_Center_B_cell_Origin --&gt; BCL2_Overexpression_and_Apoptosis_Resistance
    Germinal_Center_B_cell_Origin --&gt; MYC_Driven_Proliferation
    BCL2_Overexpression_and_Apoptosis_Resistance --&gt; Lymphoma_Cell_Accumulation
    MYC_Driven_Proliferation --&gt; Lymphoma_Cell_Accumulation
    NF_kB_Constitutive_Activation --&gt; Lymphoma_Cell_Accumulation

    style Lymphoma_Cell_Accumulation fill:#dbeafe
    style BCL2_Overexpression_and_Apoptosis_Resistance fill:#dbeafe
    style MYC_Driven_Proliferation fill:#dbeafe
    style NF_kB_Constitutive_Activation fill:#dbeafe
    style Germinal_Center_B_cell_Origin fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Blood<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Cardiovascular<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Constitutional<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Growth<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Blood
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Anemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001903" target="_blank">
                                Anemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001903)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lymphadenopathy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002716" target="_blank">
                                Lymphadenopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002716)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Splenomegaly
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001744" target="_blank">
                                Splenomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001744)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Night Sweats
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0030166" target="_blank">
                                Night sweats
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0030166)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Weight Loss
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                                Weight loss
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001824)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BCL2 Translocation
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(GCB Subtype Marker)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MYC Rearrangement
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Adverse Prognostic Marker)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MYD88 L265P Mutation
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(ABC Subtype Marker)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BCL6 Rearrangement
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Lymphoma Driver)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    R-CHOP Immunochemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Polatuzumab Vedotin plus R-CHP
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intensive Chemotherapy for Double-Hit Lymphoma
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    CAR-T Cell Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001002" target="_blank">
                            MAXO:0001002
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Autologous Stem Cell Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000747" target="_blank">
                            MAXO:0000747
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiation Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000014" target="_blank">
                            MAXO:0000014
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Tissue Biopsy and Immunohistochemistry
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    FISH for Translocations
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Diffuse Large B-Cell Lymphoma
creation_date: &#39;2026-01-26T02:55:13Z&#39;
updated_date: &#39;2026-01-26T04:02:22Z&#39;
description: &gt;-
  Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma,
  representing 30-40% of cases. It is characterized by diffuse proliferation of large
  B-lymphoid cells and is clinically aggressive but potentially curable with
  immunochemotherapy. Gene expression profiling identifies two major molecular subtypes:
  germinal center B-cell (GCB) type with better prognosis and activated B-cell (ABC)
  type with inferior outcomes. MYC, BCL2, and BCL6 rearrangements define high-grade
  &#34;double-hit&#34; or &#34;triple-hit&#34; lymphomas with aggressive behavior. R-CHOP
  (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains standard
  frontline therapy, with novel approaches for relapsed disease.
categories:
- Hematologic Malignancy
- B-cell Neoplasm
- Non-Hodgkin Lymphoma
- Aggressive Lymphoma
parents:
- B-cell non-Hodgkin lymphoma
epidemiology:
- name: Most common non-Hodgkin lymphoma
  description: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma.
  evidence:
  - reference: PMID:40753559
    supports: SUPPORT
    snippet: &#34;Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL).&#34;
    explanation: This abstract explicitly identifies DLBCL as the most common type of NHL.
has_subtypes:
- name: Germinal Center B-cell (GCB) Type
  description: &gt;-
    DLBCL with gene expression profile resembling normal germinal center B cells.
    Characterized by expression of GCB markers (CD10, BCL6, GCET1). Often harbors
    BCL2 translocation and EZH2 mutations. Better prognosis than ABC type with
    R-CHOP, with approximately 60-70% cure rates.
- name: Activated B-cell (ABC) Type
  description: &gt;-
    DLBCL with gene expression profile resembling activated peripheral B cells.
    Shows constitutive NF-kB activation, often through mutations in CD79A/B, CARD11,
    MYD88, or deletions of A20. Inferior prognosis with standard R-CHOP. May benefit
    from targeted agents inhibiting NF-kB pathway.
- name: High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements
  description: &gt;-
    Double-hit lymphoma (DHL) with concurrent MYC and BCL2 translocations, or
    triple-hit with MYC, BCL2, and BCL6 rearrangements. Highly aggressive with
    poor outcomes to standard R-CHOP. Requires intensified therapy.
pathophysiology:
- name: Germinal Center B-cell Origin
  description: &gt;-
    DLBCL arises from germinal center or post-germinal center B cells undergoing
    somatic hypermutation and class switch recombination. These processes introduce
    DNA double-strand breaks that can lead to oncogenic translocations. The cell
    of origin determines molecular subtype and clinical behavior.
  cell_types:
  - preferred_term: centrocyte
    term:
      id: CL:0009111
      label: centrocyte
  - preferred_term: centroblast
    term:
      id: CL:0009112
      label: centroblast
  locations:
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  downstream:
  - target: BCL2 Overexpression and Apoptosis Resistance
    description: BCL2 translocation blocks germinal center apoptosis
  - target: MYC-Driven Proliferation
    description: MYC rearrangement drives uncontrolled proliferation
- name: BCL2 Overexpression and Apoptosis Resistance
  description: &gt;-
    BCL2 translocation t(14;18) occurs in approximately 30% of GCB-DLBCL, placing
    BCL2 under immunoglobulin enhancer control. Resulting BCL2 overexpression
    blocks the mitochondrial apoptosis pathway, allowing survival of cells that
    would normally die in the germinal center.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Lymphoma Cell Accumulation
    description: Apoptosis resistance enables lymphoma expansion
- name: MYC-Driven Proliferation
  description: &gt;-
    MYC rearrangements occur in 10-15% of DLBCL, most commonly with IGH but also
    with non-immunoglobulin partners. MYC overexpression drives cellular proliferation
    and metabolism. When combined with BCL2 rearrangement (double-hit lymphoma),
    creates highly aggressive disease.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Lymphoma Cell Accumulation
    description: MYC drives rapid proliferation of lymphoma cells
- name: NF-kB Constitutive Activation
  description: &gt;-
    ABC-DLBCL shows constitutive NF-kB activation through various mechanisms
    including BCR signaling mutations (CD79A/B), CARD11 mutations, MYD88 L265P
    mutation, or A20 deletion. NF-kB promotes survival and contributes to the
    aggressive behavior of ABC subtype.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: signal transduction
    modifier: INCREASED
    term:
      id: GO:0007165
      label: signal transduction
  downstream:
  - target: Lymphoma Cell Accumulation
    description: NF-kB signaling promotes lymphoma survival
- name: Lymphoma Cell Accumulation
  description: &gt;-
    The combination of blocked apoptosis, enhanced proliferation, and constitutive
    survival signaling leads to aggressive expansion of large B-cell lymphoma
    involving lymph nodes and extranodal sites.
  locations:
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
histopathology:
- name: Diffuse Large B-Cell Lymphoma
  finding_term:
    preferred_term: Diffuse Large B-Cell Lymphoma
    term:
      id: NCIT:C8851
      label: Diffuse Large B-Cell Lymphoma
  frequency: VERY_FREQUENT
  description: Diffuse large B-cell lymphoma is the most common pathologic subtype.
  evidence:
  - reference: PMID:16613685
    supports: SUPPORT
    snippet: &#34;Diffuse large B-cell lymphoma is the most common pathologic subtype.&#34;
    explanation: Abstract notes DLBCL as the most common pathologic subtype.

phenotypes:
- category: Lymphatic
  name: Lymphadenopathy
  frequency: VERY_FREQUENT
  description: &gt;-
    Rapidly enlarging lymphadenopathy is the most common presentation.
    Nodal disease may be localized or widespread.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- category: Constitutional
  name: Night Sweats
  frequency: FREQUENT
  description: &gt;-
    B symptoms including drenching night sweats indicate active disease
    and are incorporated into staging.
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
- category: Constitutional
  name: Weight Loss
  frequency: FREQUENT
  description: &gt;-
    Unintentional weight loss greater than 10% body weight in 6 months
    is a B symptom with prognostic significance.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  name: Fatigue
  frequency: VERY_FREQUENT
  description: &gt;-
    Fatigue from disease burden, cytokine release, and anemia.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Abdominal
  name: Splenomegaly
  frequency: OCCASIONAL
  description: &gt;-
    Spleen involvement occurs in some cases, particularly with
    advanced stage disease.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: &gt;-
    Anemia may result from bone marrow infiltration, hemolysis,
    or cytokine effects.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
biochemical:
- name: Tissue Biopsy and Immunohistochemistry
  notes: &gt;-
    Diagnosis requires tissue biopsy showing diffuse large B cells. IHC panel
    includes CD20, CD3, CD10, BCL6, MUM1/IRF4, BCL2, MYC, and Ki-67.
    Hans algorithm (CD10, BCL6, MUM1) classifies GCB vs non-GCB subtypes.
- name: FISH for Translocations
  notes: &gt;-
    FISH testing for MYC, BCL2, and BCL6 rearrangements is essential to
    identify high-grade double-hit or triple-hit lymphomas, which require
    intensified treatment approaches.
genetic:
- name: BCL2 Translocation
  association: GCB Subtype Marker
  notes: &gt;-
    The t(14;18)(q32;q21) translocation occurs in 30% of GCB-DLBCL, placing
    BCL2 under IGH enhancer control. When combined with MYC rearrangement,
    defines double-hit lymphoma with aggressive behavior.
- name: MYC Rearrangement
  association: Adverse Prognostic Marker
  notes: &gt;-
    MYC translocations occur in 10-15% of DLBCL. MYC rearrangement with
    BCL2 and/or BCL6 defines high-grade B-cell lymphoma (double/triple hit)
    with poor prognosis requiring intensified therapy.
- name: MYD88 L265P Mutation
  association: ABC Subtype Marker
  notes: &gt;-
    MYD88 L265P is present in 30% of ABC-DLBCL and drives NF-kB activation
    through TLR signaling. Associated with extranodal disease, particularly
    CNS and testicular involvement.
- name: BCL6 Rearrangement
  association: Lymphoma Driver
  notes: &gt;-
    BCL6 translocations occur in 30% of DLBCL and may contribute to
    oncogenesis. BCL6 is a transcriptional repressor essential for germinal
    center function.
treatments:
- name: R-CHOP Immunochemotherapy
  description: &gt;-
    Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and
    prednisone is the standard frontline regimen. Six cycles cure approximately
    60% of patients overall, with better outcomes in GCB subtype and localized
    disease.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
    - preferred_term: doxorubicin
      term:
        id: CHEBI:28748
        label: doxorubicin
    - preferred_term: vincristine
      term:
        id: CHEBI:28445
        label: vincristine
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
- name: Polatuzumab Vedotin plus R-CHP
  description: &gt;-
    CD79b-directed antibody-drug conjugate combined with rituximab,
    cyclophosphamide, doxorubicin, and prednisone. Approved as frontline
    therapy providing improved outcomes compared to R-CHOP.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Intensive Chemotherapy for Double-Hit Lymphoma
  description: &gt;-
    High-grade lymphomas with MYC and BCL2 rearrangements require intensified
    regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP.
    Outcomes remain inferior to non-double-hit DLBCL.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: CAR-T Cell Therapy
  description: &gt;-
    CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel,
    tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or
    more prior lines. Achieves durable remissions in 30-40% of patients.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: MAXO:0001002
      label: immunotherapy procedure
- name: Autologous Stem Cell Transplantation
  description: &gt;-
    For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT
    remains standard. CAR-T cells are alternative for transplant-eligible and
    -ineligible patients with relapsed disease.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
- name: Radiation Therapy
  description: &gt;-
    Consolidative radiation for localized (stage I-II) disease after
    abbreviated chemotherapy improves local control. Involved-site
    radiation therapy (ISRT) is standard approach.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
disease_term:
  preferred_term: diffuse large B-cell lymphoma
  term:
    id: MONDO:0018905
    label: diffuse large B-cell lymphoma

classifications:
  icdo_morphology:
    classification_value: Lymphoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: hematologic malignancy
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Diffuse_Large_B_Cell_Lymphoma.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>